Lasch K - Search Results

1

Effects of vedolizumab on health-related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial.

Feagan BG, Patel H, Colombel JF, Rubin DT, James A, Mody R, Lasch K. Feagan BG, et al. Among authors: lasch k. Aliment Pharmacol Ther. 2017 Jan;45(2):264-275. doi: 10.1111/apt.13852. Epub 2016 Nov 17. Aliment Pharmacol Ther. 2017. PMID: 27859410 Free PMC article. Clinical Trial.

2

Seasonal patterns of abdominal pain consultations among adults and children.

Saps M, Hudgens S, Mody R, Lasch K, Harikrishnan V, Baum C. Saps M, et al. Among authors: lasch k. J Pediatr Gastroenterol Nutr. 2013 Mar;56(3):290-6. doi: 10.1097/MPG.0b013e3182769796. J Pediatr Gastroenterol Nutr. 2013. PMID: 23059641

3

Risk of developing colorectal cancer and benign colorectal neoplasm in patients with chronic constipation.

Guérin A, Mody R, Fok B, Lasch KL, Zhou Z, Wu EQ, Zhou W, Talley NJ. Guérin A, et al. Among authors: lasch kl. Aliment Pharmacol Ther. 2014 Jul;40(1):83-92. doi: 10.1111/apt.12789. Epub 2014 May 15. Aliment Pharmacol Ther. 2014. PMID: 24832002 Free article.

4

Prevalence and risk of developing comorbid conditions in patients with chronic constipation.

Mody R, Guérin A, Fok B, Lasch KL, Zhou Z, Wu EQ, Zhou W, Talley NJ. Mody R, et al. Curr Med Res Opin. 2014 Dec;30(12):2505-13. doi: 10.1185/03007995.2014.964854. Epub 2014 Sep 25. Curr Med Res Opin. 2014. PMID: 25215427

5

Changes in Practice Patterns of Clopidogrel in Combination with Proton Pump Inhibitors after an FDA Safety Communication.

Guérin A, Mody R, Carter V, Ayas C, Patel H, Lasch K, Wu E. Guérin A, et al. Among authors: lasch k. PLoS One. 2016 Jan 4;11(1):e0145504. doi: 10.1371/journal.pone.0145504. eCollection 2016. PLoS One. 2016. PMID: 26727382 Free PMC article.

6

Gastroenterologists' Perceptions Regarding Ulcerative Colitis and Its Management: Results from a Large-Scale Survey.

Lasch K, Liu S, Ursos L, Mody R, King-Concialdi K, DiBonaventura M, Leberman J, Dubinsky M. Lasch K, et al. Adv Ther. 2016 Oct;33(10):1715-1727. doi: 10.1007/s12325-016-0393-7. Epub 2016 Aug 10. Adv Ther. 2016. PMID: 27509887 Free PMC article.

7

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy.

Sands BE, Sandborn WJ, Van Assche G, Lukas M, Xu J, James A, Abhyankar B, Lasch K. Sands BE, et al. Among authors: lasch k. Inflamm Bowel Dis. 2017 Jan;23(1):97-106. doi: 10.1097/MIB.0000000000000979. Inflamm Bowel Dis. 2017. PMID: 27930408 Clinical Trial.

8

Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn's Disease Patients Stratified by Age.

Yajnik V, Khan N, Dubinsky M, Axler J, James A, Abhyankar B, Lasch K. Yajnik V, et al. Among authors: lasch k. Adv Ther. 2017 Feb;34(2):542-559. doi: 10.1007/s12325-016-0467-6. Epub 2017 Jan 9. Adv Ther. 2017. PMID: 28070861 Free PMC article. Clinical Trial.

9

Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease.

Mahadevan U, Vermeire S, Lasch K, Abhyankar B, Bhayat F, Blake A, Dubinsky M. Mahadevan U, et al. Among authors: lasch k. Aliment Pharmacol Ther. 2017 Apr;45(7):941-950. doi: 10.1111/apt.13960. Epub 2017 Feb 7. Aliment Pharmacol Ther. 2017. PMID: 28169436

10

Editorial: vedolizumab in pregnancy - is gut selectivity as good for baby as it is for mum? Authors' reply.

Mahadevan U, Vermeire S, Lasch K, Abhyankar B, Bhayat F, Blake A, Dubinsky M. Mahadevan U, et al. Among authors: lasch k. Aliment Pharmacol Ther. 2017 May;45(9):1284. doi: 10.1111/apt.14054. Aliment Pharmacol Ther. 2017. PMID: 28370036 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

82 results

Search Page

Filters